0

HINT: Hierarchical Interaction Network for Trial Outcome Prediction Leveraging Web Data

Hierarchical INteraction Network (HINT) predicts clinical trial outcomes using multi-modal web data and a dynamic attentive graph neural network, achieving strong performance across different trial phases.

Year
2021
Venue
arXiv 2021
Authors
5
Hosting
Abstract onlyARXIV-DEFAULT

Cite

Notes

Only stored in your browser.

Attribution

Abstract & full text
arxiv.org/abs/2102.04252v3ARXIV-DEFAULT
TL;DR
Semantic Scholar
Attribution policy →

Abstract

Clinical trials are crucial for drug development but are time consuming, expensive, and often burdensome on patients. More importantly, clinical trials face uncertain outcomes due to issues with efficacy, safety, or problems with patient recruitment. If we were better at predicting the results of clinical trials, we could avoid having to run trials that will inevitably fail more resources could be devoted to trials that are likely to succeed. In this paper, we propose Hierarchical INteraction Network (HINT) for more general, clinical trial outcome predictions for all diseases based on a comprehensive and diverse set of web data including molecule information of the drugs, target disease information, trial protocol and biomedical knowledge. HINT first encode these multi-modal data into latent embeddings, where an imputation module is designed to handle missing data. Next, these embeddings will be fed into the knowledge embedding module to generate knowledge embeddings that are pretrained using external knowledge on pharmaco-kinetic properties and trial risk from the web. Then the interaction graph module will connect all the embedding via domain knowledge to fully capture various trial components and their complex relations as well as their influences on trial outcomes. Finally, HINT learns a dynamic attentive graph neural network to predict trial outcome. Comprehensive experimental results show that HINT achieves strong predictive performance, obtaining 0.772, 0.607, 0.623, 0.703 on PR-AUC for Phase I, II, III, and indication outcome prediction, respectively. It also consistently outperforms the best baseline method by up to 12.4% on PR-AUC.

Authors

5